Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer.

Chen J, Niu N, Zhang J, Qi L, Shen W, Donkena KV, Feng Z, Liu J.

Curr Cancer Drug Targets. 2019;19(5):360-367. doi: 10.2174/1568009618666180703154233.

PMID:
29968537
2.

Whole Blood mRNA Expression-Based Prognosis of Metastatic Renal Cell Carcinoma.

Giridhar KV, Sosa CP, Hillman DW, Sanhueza C, Dalpiaz CL, Costello BA, Quevedo FJ, Pitot HC, Dronca RS, Ertz D, Cheville JC, Donkena KV, Kohli M.

Int J Mol Sci. 2017 Nov 3;18(11). pii: E2326. doi: 10.3390/ijms18112326.

3.

Whole blood defensin mRNA expression is a predictive biomarker of docetaxel response in castration-resistant prostate cancer.

Kohli M, Young CY, Tindall DJ, Nandy D, McKenzie KM, Bevan GH, Donkena KV.

Onco Targets Ther. 2015 Jul 30;8:1915-22. doi: 10.2147/OTT.S86637. eCollection 2015.

4.

Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth.

Wu Q, Kohli M, Bergen HR 3rd, Cheville JC, Karnes RJ, Cao H, Young CY, Tindall DJ, McNiven MA, Donkena KV.

Mol Cancer Ther. 2014 May;13(5):1067-77. doi: 10.1158/1535-7163.MCT-13-0699. Epub 2014 Mar 27.

5.

Global methylation profiling for risk prediction of prostate cancer.

Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG, Tindall DJ, Donkena KV.

Clin Cancer Res. 2012 May 15;18(10):2882-95. doi: 10.1158/1078-0432.CCR-11-2090.

6.

Antiangiogenic Effects and Therapeutic Targets of Azadirachta indica Leaf Extract in Endothelial Cells.

Mahapatra S, Young CY, Kohli M, Karnes RJ, Klee EW, Holmes MW, Tindall DJ, Donkena KV.

Evid Based Complement Alternat Med. 2012;2012:303019. doi: 10.1155/2012/303019. Epub 2012 Feb 22.

7.

Batch effect correction for genome-wide methylation data with Illumina Infinium platform.

Sun Z, Chai HS, Wu Y, White WM, Donkena KV, Klein CJ, Garovic VD, Therneau TM, Kocher JP.

BMC Med Genomics. 2011 Dec 16;4:84. doi: 10.1186/1755-8794-4-84.

8.

Vitamin d, sunlight and prostate cancer risk.

Donkena KV, Young CY.

Adv Prev Med. 2011;2011:281863. doi: 10.4061/2011/281863. Epub 2011 Jun 8.

9.

Novel molecular targets of Azadirachta indica associated with inhibition of tumor growth in prostate cancer.

Mahapatra S, Karnes RJ, Holmes MW, Young CY, Cheville JC, Kohli M, Klee EW, Tindall DJ, Donkena KV.

AAPS J. 2011 Sep;13(3):365-77. doi: 10.1208/s12248-011-9279-4. Epub 2011 May 11.

10.

Vitamin Bs, one carbon metabolism and prostate cancer.

Donkena KV, Yuan H, Young CY.

Mini Rev Med Chem. 2010 Dec;10(14):1385-92. Review.

PMID:
20937030
11.

Oxidative stress and DNA methylation in prostate cancer.

Donkena KV, Young CY, Tindall DJ.

Obstet Gynecol Int. 2010;2010:302051. doi: 10.1155/2010/302051. Epub 2010 Jun 29.

12.

Recent advances in understanding hormonal therapy resistant prostate cancer.

Donkena KV, Yuan H, Young CY.

Curr Cancer Drug Targets. 2010 Jun;10(4):402-10. Review.

PMID:
20464780
13.

Vitamins and prostate cancer risk.

Donkena KV, Karnes RJ, Young CY.

Molecules. 2010 Mar 12;15(3):1762-83. doi: 10.3390/molecules15031762. Review.

14.

Sodium selenite inhibits interleukin-6-mediated androgen receptor activation in prostate cancer cells via upregulation of c-Jun.

Gazi MH, Gong A, Donkena KV, Young CY.

Clin Chim Acta. 2007 May 1;380(1-2):145-50. Epub 2007 Feb 11.

Supplemental Content

Loading ...
Support Center